Peter Maybarduk expressed concerns about Bavarian Nordic's approach, stating that their refusal to offer a lower, transparent price for mpox vaccines during a global health emergency could result in suffering and inequitable access. He highlighted how the lack of affordable pricing might mirror the 'vaccine apartheid' seen with COVID-19, ultimately prioritizing profits over public health needs in desperate times.
Bavarian Nordic remains ambiguous on pricing strategies, leading to significant concerns. The spokesperson mentioned that the company does not prioritize discussions around price, indicating a stark disregard for producing affordable treatments during the current mpox outbreak.
[
Collection
]
[
|
...
]